WO2005041855A3 - Arzneimittelformulierung, enthaltend einen ltb4-antagonisten, sowie verfahren zu deren herstellung und deren verwendung - Google Patents

Arzneimittelformulierung, enthaltend einen ltb4-antagonisten, sowie verfahren zu deren herstellung und deren verwendung Download PDF

Info

Publication number
WO2005041855A3
WO2005041855A3 PCT/EP2004/012015 EP2004012015W WO2005041855A3 WO 2005041855 A3 WO2005041855 A3 WO 2005041855A3 EP 2004012015 W EP2004012015 W EP 2004012015W WO 2005041855 A3 WO2005041855 A3 WO 2005041855A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
pharmaceutical formulation
formulation containing
ltb4 antagonist
active substance
Prior art date
Application number
PCT/EP2004/012015
Other languages
English (en)
French (fr)
Other versions
WO2005041855A2 (de
Inventor
Thomas Bock
Siglinde Moll
Karl Weber
Ulrich Brauns
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Thomas Bock
Siglinde Moll
Karl Weber
Ulrich Brauns
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Thomas Bock, Siglinde Moll, Karl Weber, Ulrich Brauns filed Critical Boehringer Ingelheim Int
Priority to JP2006537151A priority Critical patent/JP2007513068A/ja
Priority to EP04790806A priority patent/EP1682086A2/de
Priority to BRPI0416121-1A priority patent/BRPI0416121A/pt
Priority to MXPA06004435A priority patent/MXPA06004435A/es
Priority to CA002544049A priority patent/CA2544049A1/en
Priority to AU2004285271A priority patent/AU2004285271A1/en
Publication of WO2005041855A2 publication Critical patent/WO2005041855A2/de
Priority to IL175293A priority patent/IL175293A0/en
Publication of WO2005041855A3 publication Critical patent/WO2005041855A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft eine neue Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten der Formel (I) worin A, R1, R2, R3 und R4 die in Anspruch 1 angegebene Bedeutung aufweisen, dessen pharmakologisch akzeptables Säureadditionssalz, Glykosid, O-Sulfat oder Glucuronid als Wirkstoff sowie gegebenenfalls mindestens einen pharmakologisch akzeptablen Hilfsstoff und/oder Träger, wobei der Wirkstoff als feste Lösung oder feste Dispersion in einer Polymermatrix vorliegt. Gegenstand der Erfindung ist auch deren Herstellung sowie die Verwendung als Arzneimittel sowie die festen Lösungen und Dispersionen an sich.
PCT/EP2004/012015 2003-10-29 2004-10-23 Arzneimittelformulierung, enthaltend einen ltb4-antagonisten, sowie verfahren zu deren herstellung und deren verwendung WO2005041855A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2006537151A JP2007513068A (ja) 2003-10-29 2004-10-23 Ｌｔｂ４−アンタゴニストを含む医薬製剤、並びにその調製方法及びその使用
EP04790806A EP1682086A2 (de) 2003-10-29 2004-10-23 Arzneimittelformulierung, enthaltend einen ltb4-antagonisten, sowie verfahren zu deren herstellung und deren verwendung
BRPI0416121-1A BRPI0416121A (pt) 2003-10-29 2004-10-23 formulação medicamentosa contendo um antagonista ltb4 bem como processo para sua preparação e seu uso
MXPA06004435A MXPA06004435A (es) 2003-10-29 2004-10-23 Formulacion farmaceutica que contiene un antagonista de ltd4, asi como procedimiento para su preparacion y su uso.
CA002544049A CA2544049A1 (en) 2003-10-29 2004-10-23 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof
AU2004285271A AU2004285271A1 (en) 2003-10-29 2004-10-23 Pharmaceutical formulation containing an LTB4 antagonist, method for the production thereof, and use thereof
IL175293A IL175293A0 (en) 2003-10-29 2006-04-27 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10350528A DE10350528A1 (de) 2003-10-29 2003-10-29 Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung
DE10350528.8 2003-10-29

Publications (2)

Publication Number Publication Date
WO2005041855A2 WO2005041855A2 (de) 2005-05-12
WO2005041855A3 true WO2005041855A3 (de) 2007-05-10

Family

ID=34529886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012015 WO2005041855A2 (de) 2003-10-29 2004-10-23 Arzneimittelformulierung, enthaltend einen ltb4-antagonisten, sowie verfahren zu deren herstellung und deren verwendung

Country Status (14)

Country Link
US (1) US20050129768A1 (de)
EP (1) EP1682086A2 (de)
JP (1) JP2007513068A (de)
KR (1) KR20060108696A (de)
CN (1) CN101123950A (de)
AU (1) AU2004285271A1 (de)
BR (1) BRPI0416121A (de)
CA (1) CA2544049A1 (de)
DE (1) DE10350528A1 (de)
IL (1) IL175293A0 (de)
MX (1) MXPA06004435A (de)
RU (1) RU2006118273A (de)
WO (1) WO2005041855A2 (de)
ZA (1) ZA200601360B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237823A1 (en) * 2004-05-04 2007-10-11 Thomas Bock Solid Pharmaceutical Form Comprising and Ltb4 Antagonist
EP3623368A4 (de) 2017-05-12 2021-04-07 Riken Modifikator einer verbindung mit klasse-a-gpcr-bindung

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002497A1 (de) * 1994-07-13 1996-02-01 Boehringer Ingelheim Kg Substituierte benzamidine, ihre herstellung und verwendung als arzneimittel
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
EP1120120A1 (de) * 1998-10-05 2001-08-01 Eisai Co., Ltd. Tableten die sich unmittelbar in der mundhöhle auflösen
WO2001089574A1 (en) * 2000-05-20 2001-11-29 Sang Deuk Lee Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
WO2003070279A1 (en) * 2002-02-20 2003-08-28 Altana Pharma Ag Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002497A1 (de) * 1994-07-13 1996-02-01 Boehringer Ingelheim Kg Substituierte benzamidine, ihre herstellung und verwendung als arzneimittel
EP1120120A1 (de) * 1998-10-05 2001-08-01 Eisai Co., Ltd. Tableten die sich unmittelbar in der mundhöhle auflösen
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
WO2001089574A1 (en) * 2000-05-20 2001-11-29 Sang Deuk Lee Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
WO2003070279A1 (en) * 2002-02-20 2003-08-28 Altana Pharma Ag Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

Also Published As

Publication number Publication date
WO2005041855A2 (de) 2005-05-12
US20050129768A1 (en) 2005-06-16
EP1682086A2 (de) 2006-07-26
CN101123950A (zh) 2008-02-13
CA2544049A1 (en) 2005-05-12
JP2007513068A (ja) 2007-05-24
DE10350528A1 (de) 2005-06-09
RU2006118273A (ru) 2007-12-20
AU2004285271A1 (en) 2005-05-12
MXPA06004435A (es) 2006-06-20
ZA200601360B (en) 2007-03-28
BRPI0416121A (pt) 2007-01-02
KR20060108696A (ko) 2006-10-18
IL175293A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
EP2177220B1 (de) Pirfenidon enthaltendes gel
CA2535364A1 (en) Hyaluronic acid nanoparticles
EP1982982A4 (de) Neues coumarinderivat mit antitumorwirkung
WO2006077025A3 (en) Morpholines as 5ht2c agonists
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
CN1434796A (zh) 酰基苯基脲衍生物,其制备方法和作为药物的用途
GEP20032967B (en) Indolyl-3-Glyoxylic Acid Derivatives As an Antitumor Agent and Pharmaceutical Composition
WO2002081453A8 (fr) Hiohydantoïnes et leur utilisation dans le traitement du diabete
UA94065C2 (en) Dihydropseudoerythromycin derivatives
WO2006117211A3 (en) Urea derivatives methods for their manufacture and uses thereof
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
BR0308056A (pt) Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
WO2004100865A3 (en) New benzimidazole derivatives
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
CA2530308A1 (en) 5ht2c receptor agonists for the treatment of diabetes and obesity
EP1619180A4 (de) Casr-antagonist
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2007058568A3 (fr) Sels et melanges d'acide 9-oxoacridine-10-acetique et de 1-alkylamino-1-desoxypolyols, compositions pharmaceutiques les contenant, et methodes de traitement associees
EP1935417A4 (de) Zusammensetzung zur prävention von hypoglykämischen zuständen
CA2356959A1 (en) Water-insoluble drug delivery system
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480032290.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006/01360

Country of ref document: ZA

Ref document number: 200601360

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004790806

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2025/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/004435

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 175293

Country of ref document: IL

Ref document number: 12006500843

Country of ref document: PH

Ref document number: 2544049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006537151

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004285271

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 547432

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006118273

Country of ref document: RU

Ref document number: 1020067010481

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004285271

Country of ref document: AU

Date of ref document: 20041023

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004285271

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004790806

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067010481

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0416121

Country of ref document: BR